Psychotic disorders in adolescents present acute and long-term challenges, including those of differential diagnosis, prognosis and treatment choices (Kafantaris et al. 1996, 1998). When lithium became widely available in the U.S., much attention was paid to differential diagnosis of mood disorders with psychotic features from schizophrenia because, for some patients, lithium was more effective than first-generation antipsychotics (Janicak et al.1992). Second generation antipsychotics (SGAs) have been shown to be efficacious as monotherapy for the treatment of acute mania (Perils et al. 2006) and to increase response rates when added to a traditional mood stabilizer, including in adolescents with or without psychotic features (Del Bello et al. 2002). In a small study, adolescents who had prominent psychotic features at study entry appeared to benefit from continuing adjunctive treatment with an antipsychotic agent despite ongoing lithium treatment (Kafantaris et al. 2001a, 2001b). As many of the treatments approved for bipolar disorder now converge with those used for schizophrenia, pinpointing the exact diagnosis, particularly in adolescents, may seem less crucial and call into question whether treatment with traditional mood stabilizers for bipolar disorder with psychotic features is even necessary. Moreover, although the addition of valproate to a first-generation antipsychotic resulted in a higher acute response rate in one adult study (Muller-Oerlinghausen et all 2000), it is not known whether it is beneficial to add a traditional mood stabilizer to a SGA for acute and continuation the treatment of psychotic mania. This is an important question, particulariy for adolescents, as the treatment of an early psychotic episode has significant impact on course of illness and developmental outcome. The proposed study is a placebo-controlled, parallel group, randomized clinical trial comparing two treatment strategies in adolescents with mania and prominent psychotic features. One group will receive a SGA and placebo and the other will receive a SGA and lithium. During the acute treatment phase, the possible benefits of adding lithium to a SGA include a higher proportion of responders, shorter time to response, and potentially a lower dose of SGA. For continuation treatment, possible benefits include prophylaxis against episodes of depression. Results from this study will inform the design of a more definitive trial.
Specific aims are: 1. To assess the efficacy and safety of adjunctive lithium in the acute treatment of mania with psychotic features in adolescents. 2. To assess the efficacy and safety of adjunctive lithium in the prophylaxis against recurrence of mood episodes with psychotic features in adolescents over a six month follow-up period.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZMH1-ERB-N)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Feinstein Institute for Medical Research
United States
Zip Code
John, Majnu; Lencz, Todd; Ferbinteanu, Janina et al. (2017) Applications of temporal kernel canonical correlation analysis in adherence studies. Stat Methods Med Res 26:2437-2454
Lyall, A E; Pasternak, O; Robinson, D G et al. (2017) Greater extracellular free-water in first-episode psychosis predicts better neurocognitive functioning. Mol Psychiatry :
Galling, Britta; Roldán, Alexandra; Hagi, Katsuhiko et al. (2017) Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 16:77-89
Robinson, Delbert G; Schooler, Nina R; Correll, Christoph U et al. (2017) Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. Am J Psychiatry :appiajp201716080919
McNamara, Robert K; Szeszko, Philip R; Smesny, Stefan et al. (2017) Polyunsaturated fatty acid biostatus, phospholipase A2 activity and brain white matter microstructure across adolescence. Neuroscience 343:423-433
Browne, Julia; Penn, David L; Meyer-Kalos, Piper S et al. (2017) Psychological well-being and mental health recovery in the NIMH RAISE early treatment program. Schizophr Res 185:167-172
DeRosse, Pamela; Ikuta, Toshikazu; Karlsgodt, Katherine H et al. (2017) White Matter Abnormalities Associated With Subsyndromal Psychotic-Like Symptoms Predict Later Social Competence in Children and Adolescents. Schizophr Bull 43:152-159
John, Majnu; Ikuta, Toshikazu; Ferbinteanu, Janina (2017) Graph analysis of structural brain networks in Alzheimer's disease: beyond small world properties. Brain Struct Funct 222:923-942
Birnbaum, Michael L; Rizvi, Asra F; Confino, Jamie et al. (2017) Role of social media and the Internet in pathways to care for adolescents and young adults with psychotic disorders and non-psychotic mood disorders. Early Interv Psychiatry 11:290-295
Kane, John M; Robinson, Delbert G; Schooler, Nina R et al. (2016) Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. Am J Psychiatry 173:362-72

Showing the most recent 10 out of 105 publications